Related references
Note: Only part of the references are listed.Innovations in CRISPR-Based Therapies
Gokul Kesavan
MOLECULAR BIOTECHNOLOGY (2023)
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
Si-Wei Wang et al.
MOLECULAR CANCER (2022)
Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV
Meisam Naeimi Kararoudi et al.
CELL REPORTS METHODS (2022)
The Role of Recombinant AAV in Precise Genome Editing
Swati Bijlani et al.
FRONTIERS IN GENOME EDITING (2022)
dbGuide: a database of functionally validated guide RNAs for genome editing in human and mouse cells
Alexander A. Gooden et al.
NUCLEIC ACIDS RESEARCH (2021)
CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Yongxian Hu et al.
CLINICAL CANCER RESEARCH (2021)
CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research
Yue Yang et al.
FRONTIERS IN MEDICINE (2021)
CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease
Selami Demirci et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2021)
The NIH Somatic Cell Genome Editing program
Krishanu Saha et al.
NATURE (2021)
Recombinant protein TRAIL-Mu3 enhances the antitumor effects in pancreatic cancer cells by strengthening the apoptotic signaling pathway
Min Huang et al.
ONCOLOGY LETTERS (2021)
Rapid target validation in a Cas9-inducible hiPSC derived kidney model
Yasaman Shamshirgaran et al.
SCIENTIFIC REPORTS (2021)
Implementing Novel Designs in pET Expression Plasmids that Increase Protein Production
Patrick J. Shilling et al.
BIO-PROTOCOL (2021)
Promising therapeutic approaches using CRISPR/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy
Hasan Mollanoori et al.
GENES & DISEASES (2021)
Improved designs for pET expression plasmids increase protein production yield in Escherichia coli
Patrick J. Shilling et al.
COMMUNICATIONS BIOLOGY (2020)
First Trial of CRISPR-Edited T cells in Lung Cancer
Simon F. Lacey et al.
TRENDS IN MOLECULAR MEDICINE (2020)
Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy
Christopher E. Nelson et al.
NATURE MEDICINE (2019)
Correction of IVS I-110(G>A) β-thalassemia by CRISPR/Cas- and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells
Petros Patsali et al.
HAEMATOLOGICA (2019)
High levels of AAV vector integration into CRISPR-induced DNA breaks
Killian S. Hanlon et al.
NATURE COMMUNICATIONS (2019)
A Drosophila Tumor Suppressor Gene Prevents Tonic TNF Signaling through Receptor N-Glycosylation
Geert de Vreede et al.
DEVELOPMENTAL CELL (2018)
Regulation of TNF-Related Apoptosis-Inducing Ligand Signaling by Glycosylation
Olivier Micheau
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells
Akiko Seki et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Galectins Control mTOR in Response to Endomembrane Damage
Jingyue Jia et al.
MOLECULAR CELL (2018)
CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens
Jean-Paul Concordet et al.
NUCLEIC ACIDS RESEARCH (2018)
The CRISPR tool kit for genome editing and beyond
Mazhar Adli
NATURE COMMUNICATIONS (2018)
TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress
Florent Dufour et al.
ONCOTARGET (2017)
TRAIL mutant membrane penetrating peptide alike (TMPPA) TRAIL-Mu3 enhances the antitumor effects of TRAIL in vitro and in vivo
Hong Zhu et al.
MOLECULAR MEDICINE REPORTS (2017)
A versatile system for rapid multiplex genome-edited CAR T cell generation
Jiangtao Ren et al.
ONCOTARGET (2017)
N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death
Florent Dufour et al.
CELL DEATH AND DIFFERENTIATION (2017)
Death receptor-based enrichment of Cas9-expressing cells
C. Liesche et al.
BMC BIOTECHNOLOGY (2016)
Using CRISPR-Cas9 to quantify the contributions of O-glycans, N-glycans and Glycosphingolipids to human leukocyte-endothelium adhesion
Gino Stolfa et al.
SCIENTIFIC REPORTS (2016)
DNA-free genome editing in plants with preassembled CRISPR-Cas9 ribonucleoproteins
Je Wook Woo et al.
NATURE BIOTECHNOLOGY (2015)
Improved vectors and genome-wide libraries for CRISPR screening
Neville E. Sanjana et al.
NATURE METHODS (2014)
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
Ophir Shalem et al.
SCIENCE (2014)
CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III
Elitza Deltcheva et al.
NATURE (2011)
Modulation of the CD95-Induced Apoptosis: The Role of CD95 N-Glycosylation
Olga M. Shatnyeva et al.
PLOS ONE (2011)
In-Fusion BioBrick assembly and re-engineering
Sean C. Sleight et al.
NUCLEIC ACIDS RESEARCH (2010)
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL
Klaus W. Wagner et al.
NATURE MEDICINE (2007)
Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors
C Baum et al.
HUMAN GENE THERAPY (2006)
Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex
N Holler et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule
N Holler et al.
NATURE IMMUNOLOGY (2000)
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
FC Kischkel et al.
IMMUNITY (2000)
TRAIL receptor-2 signals apoptosis through FADD and caspase-8
JL Bodmer et al.
NATURE CELL BIOLOGY (2000)
Share Paper
